Лучшие больницы для «Electrophysiology Study» в Дубай, ОАЭ

The total cost of an Electrophysiology Study (EPS) in India ranges from approximately USD 2,500 to USD 8,000, depending on whether the procedure is diagnostic-only or combined with catheter ablation (radiofrequency, cryoablation, or pulsed-field ablation), the mapping technology used (standard fluoroscopy vs. 3D electroanatomical systems such as CARTO 3 or EnSite X), and the hospital tier (NABH-accredited vs. JCI-accredited private tertiary centers in Mumbai, Delhi, Chennai, or Hyderabad). This represents a saving of 40–60% compared to equivalent procedures in the United Kingdom or United States, where the same procedure can cost USD 15,000–USD 50,000. In the UAE (Dubai and Abu Dhabi), costs for EPS range from approximately USD 5,000 to USD 15,000. UAE costs are higher than India due to premium hospital infrastructure, higher staffing costs, and the luxury patient experience, but they remain substantially lower than Western Europe or North America. UAE centers hold JCI accreditation and DHA (Dubai Health Authority) or HAAD (Abu Dhabi Health Authority) licensure, and are staffed by internationally trained cardiac electrophysiologists. GAF Healthcare provides a fully itemized cost estimate prior to travel, inclusive of the procedure, catheterization laboratory fees, catheter and mapping system costs, hospital stay, standard medications, and post-procedure monitoring. Optional inclusions such as implantable device therapy (ICD, pacemaker), advanced ablation catheters (contact-force sensing, PFA balloon), or extended ICU stay are quoted transparently. There are no hidden fees — GAF Healthcare's pricing model is built on complete pre-travel cost transparency.

The minimum in-country stay before international air travel is safe depends critically on whether the EPS was diagnostic-only or combined with catheter ablation, and on the complexity of the arrhythmia treated. For a DIAGNOSTIC-ONLY EPS (no ablation performed): Most patients can be safely discharged within 24 hours and are fit to fly within 3–5 days of the procedure. The primary requirement is confirming vascular access site healing, absence of groin hematoma, stable rhythm on telemetry, and — for anticoagulated patients — confirmed therapeutic anticoagulation re-establishment. For EPS COMBINED WITH CATHETER ABLATION: - Simple supraventricular tachycardia ablation (AVNRT, typical atrial flutter, accessory pathway): Fit to fly in 5–7 days after an uncomplicated procedure. - Atrial fibrillation ablation (pulmonary vein isolation with PFA, cryoablation, or radiofrequency): A minimum 7–10 days in-country is recommended before long-haul flight, given the risk of delayed pericardial effusion and the need for post-procedure rhythm monitoring. A 12-lead ECG and clinical review are performed at Day 5–7 before clearance. - Complex ventricular tachycardia (VT) ablation or procedures involving transseptal puncture in patients with structural heart disease: A 10–14 day in-country period is standard before flying, with consideration of an event monitor to detect early recurrence. GAF Healthcare arranges medically supervised accommodation near the partner hospital throughout the fit-to-fly observation period, with daily or alternate-day nursing check-in, and direct-line access to the electrophysiologist. All patients receive a formal 'Fit to Fly' clearance letter signed by the treating physician before departure, which satisfies airline medical travel requirements.

The success rate of EPS must be interpreted in two components: (1) the diagnostic accuracy of the study itself, and (2) the long-term clinical success of any ablation therapy that follows. DIAGNOSTIC ACCURACY OF EPS: When performed by experienced cardiac electrophysiologists using modern programmed electrical stimulation protocols and 3D electroanatomical mapping, EPS achieves a diagnostic accuracy exceeding 95% for identifying the mechanism and origin of clinically documented arrhythmias. For some conditions — such as AVNRT, accessory pathways, and typical atrial flutter — the sensitivity and specificity approach 99% under optimal induction conditions. LONG-TERM ABLATION SUCCESS RATES (BY ARRHYTHMIA TYPE): - AV Nodal Re-entrant Tachycardia (AVNRT) — Slow-pathway RF or cryo ablation: 96–98% long-term cure rate; recurrence risk <2–5%. - Accessory Pathway / WPW Syndrome: 93–97% acute success; recurrence in 5–8% (higher for septal pathways due to proximity to AV node). - Typical Right Atrial Flutter (Cavotricuspid Isthmus ablation): 90–95% long-term freedom from flutter; risk of subsequent atrial fibrillation in 25–30% of patients over 5 years. - Paroxysmal Atrial Fibrillation (Pulmonary Vein Isolation — PVI): 70–80% freedom from AF at 12 months after a single procedure; rising to 85–90% after repeat procedures. PFA technology has shown promising early data suggesting equivalent or superior outcomes with a dramatically improved safety profile. - Persistent/Long-standing Persistent AF: 50–60% single-procedure success at 12 months; adjunct ablation strategies (posterior wall isolation, complex fractionated atrial electrogram ablation) improve outcomes in carefully selected patients. - Idiopathic Ventricular Tachycardia (structurally normal heart — RVOT or fascicular VT): 85–95% acute and long-term success. - Scar-related Ventricular Tachycardia (post-MI or cardiomyopathy substrate): 60–75% freedom from VT storm at 12 months; combined epicardial-endocardial ablation approaches improve success in resistant cases. All GAF Healthcare partner centers publish their annual procedural volume and outcome data, and patients are encouraged to request center-specific success rates and operator volume statistics as part of the pre-travel informed consent process.